Insurance - Life · NYSE
Current Price
$117.80
PE Ratio (TTM)
13.0x
Intrinsic Value
$118.99
+1.0% margin of safety
As of 2026-06-12, applying a 13.0x earnings multiple to Aflac Incorporated's (AFL) earnings per share of $9.04 yields a fair value estimate of $118.99 per share, versus a market price of $117.8.
Fair value from earnings multiples is sensitive to the multiple you choose. Across the sensitivity grid the estimate spans $92.06 to $150.36. This is a relative estimate anchored to earnings, not a statement of fact. For a cash flow based view, see the intrinsic value estimate on the DCF page.
How our PE model works · Recalculate in PE mode · AFL intrinsic value (DCF view)
At $117.8, AFL trades about 1.0% below its PE-based fair value estimate, a modest discount to its earnings power, though not enough for us to call it cheap outright.
COMPETITIVE MOAT
↑Strong Brand Recognition
Aflac's duck mascot is highly recognizable, fostering trust and loyalty among its customer base. This brand equity translates into a sticky customer relationship in the supplemental insurance market.
↑Established Distribution Network
The company has a deep-rooted network of agents and brokers, particularly in the U.S. and Japan. This extensive reach makes it difficult for new entrants to replicate their market penetration.
↑Regulatory Hurdles
The insurance industry is heavily regulated, creating significant barriers to entry. Navigating these complex compliance requirements favors established players like Aflac.
INVESTMENT RISKS
↓Interest Rate Sensitivity
Aflac's investment income is sensitive to interest rate fluctuations. Declining rates can pressure profitability, impacting its ability to generate returns on its substantial investment portfolio.
↓Japan Market Concentration
A significant portion of Aflac's revenue comes from Japan. Economic downturns or regulatory changes in Japan could disproportionately affect the company's financial performance.
↓Competition in Insurance
The insurance sector is competitive, with both established insurers and new digital players vying for market share. Aflac faces ongoing pressure to innovate and maintain its competitive edge.
Base case
Intrinsic Value
$118.99
Margin of safety
+1.0%
Expected annual return
+0.2%
Base case assumptions: 2.4% annual earnings growth, 13x target PE, 10% discount rate, 5 year projection. Data as of 2026-06-12.
This base case uses default assumptions and is not financial advice. The fair value changes significantly when the target PE or earnings growth rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for Aflac Incorporated respond.
Open PE Calculator for AFLAflac Incorporated, operating through its various subsidiary companies, focuses on delivering supplementary health and life insurance policies. The firm's business activities are structured into two primary divisions: Aflac Japan and Aflac U.S. In Japan, the company offers a diverse range of insurance products, including coverage for cancer, medical expenses, income support for nursing care, and the distinct GIFT plan. This segment also provides traditional whole and term life insurance, along with savings-oriented plans like WAYS and child endowment products. Meanwhile, the Aflac U.S. division caters to the American market, furnishing policies that address cancer, accidents, short-term disability, critical illness, and hospital stays. Additionally, it provides dental, vision, long-term care, disability, and both term and whole life insurance options. Aflac distributes its comprehensive suite of products through multiple channels, which include dedicated sales associates, independent brokers, various corporate and individual agencies, and affiliated agencies. Established in 1955, the company maintains its corporate headquarters in Columbus, Georgia.
PE Ratio (TTM)
13.0x
PEG Ratio
0.35
Earnings Yield
7.67%
ROE (TTM)
17.2%
Revenue/Share (TTM)
$35.52
Dividend Yield
2.02%
Debt/Equity
0.35x
The trailing twelve-month PE ratio of AFL reflects how much investors pay per dollar of Aflac Incorporated's earnings. This metric is most useful when compared to Insurance - Life peers and the company's own historical range.
AFL's PE of 13.0x combined with a PEG ratio of 0.35 provides a growth-adjusted perspective. A PEG below 1.0 suggests AFL may be undervalued relative to its earnings growth rate. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Insurance - Life, a DCF analysis may be more appropriate.
To value Aflac Incorporated using PE: (1) Compare the current PE (13.0x) against the Insurance - Life median to assess relative pricing, (2) check the PEG ratio (0.35) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
AFL's PEG ratio is 0.35, calculated by dividing the PE ratio (13.0x) by the expected earnings growth rate. A PEG below 1.0 is traditionally considered a sign of undervaluation — the market may not be fully pricing in the growth potential. Note that PEG accuracy depends on the reliability of growth estimates.
PE ratio gives a quick relative read — how AFL is priced versus Insurance - Life peers. DCF provides an absolute value based on projected free cash flows. For AFL, with a strong ROE of 17.2%, both methods are worth using — PE for a market-relative check, DCF to stress-test whether fundamentals justify the price. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
P/E and DCF value AFL with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-06-12. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.